<DOC>
	<DOCNO>NCT00985088</DOCNO>
	<brief_summary>The purpose study characterize safety immunogenicity H1N1 ( swine ) flu vaccine GSK2340273A GSK2340274A adults 18 year age old . This protocol post updated section impact Protocol amendment 1 , Sept 2009 .</brief_summary>
	<brief_title>Safety Immunogenicity H1N1 Vaccines Adults Aged 18 Years Older</brief_title>
	<detailed_description>Collaborators : United States Department Health Human Services , Office Biomedical Advanced Research Development Authority</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Written inform consent obtain subject . Male female adult , &gt; = 18 year age time first vaccination . Safety laboratory test result within parameter specify protocol . Satisfactory baseline medical assessment history physical examination . Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit document signature inform consent document . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day first vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Medical history physicianconfirmed infection A/California/7/2009 ( H1N1 ) vlike virus Previous vaccination time H1N1vlike virus vaccine medical history physicianconfirmed infection H1N1vlike virus . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence temperature &gt; = 38.0ºC ( &gt; =100.4ºF ) , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Receipt systemic glucocorticoid within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination , eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine With exception seasonal influenza vaccination , administration vaccine ( ) within 30 day study vaccination Day 0 . Seasonal influenza vaccine may administer 14 day prior study vaccination Day 0 . Planned administration vaccine foreseen study protocol Day 0 Day 42 phlebotomy , include seasonal influenza vaccine monovalent pandemic H1N1 vaccine study vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine/product , plan use study period . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin test result prior first vaccination . Lactating nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A</keyword>
	<keyword>influenza infection</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340273A</keyword>
</DOC>